
The article analyzes options strategies for AstraZeneca (AZN), currently trading at $74.00, outlining the potential for investors to acquire shares at a discount (effective cost basis $69.02 by selling a $70.00 put) or generate enhanced yield on existing holdings (up to 14.22% annualized via a $76.00 covered call). These strategies offer defined risk/reward profiles, with probabilities of the options expiring worthless ranging from 57% to 70%. Notably, the implied volatility for the put option (37%) significantly surpasses that of the call option (27%) and the stock's historical volatility (24%), indicating a market perception of higher downside risk or demand for downside protection in AZN.
The article outlines two distinct options strategies for AstraZeneca (AZN), currently trading at $74.00 per share. For investors seeking to initiate a position, selling the $70.00 strike put contract offers a potential entry point at an effective cost basis of $69.02, representing a 5% discount to the current market price. This strategy comes with a 70% statistical probability of the option expiring worthless, which would generate an 11.88% annualized return on the required cash collateral. For existing shareholders, a covered call strategy at the $76.00 strike could yield an annualized return of 14.22% if the option expires worthless, with a 57% probability. The most critical insight from the provided data is the significant volatility skew; the implied volatility for the put option is 37%, markedly higher than the 27% for the call option and the stock's 24% actual trailing twelve-month volatility. This discrepancy indicates that the options market is pricing in a greater potential for downside price movement or a higher demand for downside protection compared to upside speculation.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment